1778 EXPRESSION OF INTEGRIN PROTEINS IN NON-MUSCLE INVASIVE BLADDER CANCER: SIGNIFICANCE OF INTRAVESICAL RECURRENCE FOLLOWING TRANSURETHRAL RESECTION

Abstract

You have accessJournal of UrologyBladder Cancer: Superficial II1 Apr 20121778 EXPRESSION OF INTEGRIN PROTEINS IN NON-MUSCLE INVASIVE BLADDER CANCER: SIGNIFICANCE OF INTRAVESICAL RECURRENCE FOLLOWING TRANSURETHRAL RESECTION Hideaki Miyake, Hosny Behnsawy, and Masato Fujisawa Hideaki MiyakeHideaki Miyake Kobe, Japan More articles by this author , Hosny BehnsawyHosny Behnsawy Kobe, Japan More articles by this author , and Masato FujisawaMasato Fujisawa Kobe, Japan More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2012.02.1795AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Intravesical recurrence after transurethral resection (TUR) has been reported to occur in approximately 50% of patients with non-muscle invasive bladder cancer. Integrins are a family of transmembrane heterodimers, many of which function as receptors for extracellular matrix molecules. To date, a few studies have investigated the role of integrins in bladder cancer progression; therefore, it remains unknown whether intergrins have a significant impact on the prognosis of patients with bladder cancer, particularly that of those with non-muscle invasive disease. The objective of this study was to evaluate the expression levels of integrins in non-muscle invasive bladder cancer to clarify the significance of these proteins as predictors of intravesical recurrence in patients treated with TUR. METHODS This study included 161 patients with non-muscle invasive bladder cancer undergoing TUR between 2000 and 2007. Expression levels of α2, α3, α5, α6, β1 and β4 integrins in TUR specimens obtained from these patients were measured by immunohistochemical staining. RESULTS Of these 6 proteins, expression level of α2, α3, α6 and β4 integrins were significantly associated with several conventional predictive factors of intravesical recurrence. Univariate analysis identified expression level of α3, α6 and β4 integrins as significant predictors of intravesical recurrence, while tumor size, pathological T stage and concomitant carcinoma in situ (CIS) were also significant. Of these significant factors, β4 integrin expression level, pathological T stage and concomitant CIS appeared to be independently related to intravesical recurrence by multivariate analysis. Furthermore, there were significant differences in recurrence-free survival according to positive numbers of these three independent risk factors; that is, intravesical recurrence occurred in 10 of 49 patients who were negative for all risk factors (20.4%), 31 of 68 positive for a single risk factor (45.6%), and 30 of 44 positive for 2 or 3 risk factors (68.2%). CONCLUSIONS Consideration of expression levels of integrins in TUR specimens, in addition to conventional prognostic parameters, would contribute to accurate prediction of intravesical recurrence following TUR for non-muscle invasive bladder cancer. Moreover, combined evaluation of β4 integrin expression, pathological T stage and concomitant CIS would be particularly useful for further refinement of the system in predicting recurrence of non-muscle invasive bladder cancer following TUR. © 2012 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 187Issue 4SApril 2012Page: e718 Advertisement Copyright & Permissions© 2012 by American Urological Association Education and Research, Inc.MetricsAuthor Information Hideaki Miyake Kobe, Japan More articles by this author Hosny Behnsawy Kobe, Japan More articles by this author Masato Fujisawa Kobe, Japan More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...